{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T21:11:53Z","timestamp":1769721113401,"version":"3.49.0"},"reference-count":132,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:00:00Z","timestamp":1326758400000},"content-version":"vor","delay-in-days":4705,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[1999,3]]},"abstract":"<jats:p>The frequency of life\u2010threatening fungal infections has increased dramatically over the past few decades. For more than 30 years amphotericin B has been the standard treatment for systemic and deep\u2010seated fungal infections, primarily because of its broad spectrum of activity. Its usefulness is limited by a relatively high frequency of significant adverse events including infusion\u2010related reactions and nephrotoxicity. In an effort to overcome these side effects, a number of lipid\u2010based formulations were developed, each with its own composition and pharmacokinetic behavior. The clinical significance of these differences is unknown. Available clinical data suggest the formulations have a reduced propensity for causing nephrotoxicity. However, considering limited efficacy data, they should be reserved as second\u2010line therapy for patients who cannot tolerate or fail an adequate trial of conventional amphotericin B or cannot benefit from other antifungal agents.<\/jats:p>","DOI":"10.1592\/phco.19.4.306.30934","type":"journal-article","created":{"date-parts":[[2004,4,27]],"date-time":"2004-04-27T10:55:45Z","timestamp":1083063345000},"page":"306-323","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Lipid\u2010Based Amphotericin B for the Treatment of Fungal Infections"],"prefix":"10.1002","volume":"19","author":[{"given":"Douglas","family":"Slain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,17]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0195-6701(88)90220-4"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/20.6.1526"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.8153622"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(97)00192-2"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/20.6.1531"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/513640"},{"key":"e_1_2_1_8_2","first-page":"2306","volume-title":"Principles and practice of infectious diseases","author":"Bennett JE","year":"1995"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.1.77"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/520274"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198909213211205"},{"key":"e_1_2_1_12_2","volume-title":"Therapy of invasive aspergillosis: disease spectrum, treatment practices, and outcomes [abstr]","author":"Patterson TF","year":"1996"},{"key":"e_1_2_1_13_2","volume-title":"Fungizone (amphotericin B) package insert","author":"Bristol\u2010Myers Squibb Co","year":"1993"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/28.suppl_B.27"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/12.2.308"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.6.1392"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1086\/516321"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(96)80072-6"},{"issue":"5","key":"e_1_2_1_19_2","first-page":"22N","article-title":"Amphotericin B revisited: reassessment of toxicity","volume":"88","author":"Clements JS","year":"1990","journal-title":"Am J Med"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V62154"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-198303000-00005"},{"key":"e_1_2_1_22_2","first-page":"229","volume-title":"Drug interaction facts. St","author":"Tatro DS","year":"1994"},{"key":"e_1_2_1_23_2","first-page":"1245","volume-title":"The use of antibiotics: a clinical review of antibacterial, antifungal and antiviral drugs","author":"Kucers A.","year":"1997"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002808001400303"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/156.5.784"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/34.6.975"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.5.906"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1987.294"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.7.1402"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1990.tb02593.x"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199104000-00043"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1988.00380110049010"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/20.4.755"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198308010-00002"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199223040-00004"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.6.1275"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/17.Supplement_2.S501"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2836(65)80093-6"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199121030-00001"},{"key":"e_1_2_1_40_2","first-page":"109","volume-title":"Liposomes: from biophysics to therapeutics","author":"Hwang KJ","year":"1987"},{"key":"e_1_2_1_41_2","first-page":"1576","article-title":"Use of liposomes as injectable\u2010drug delivery systems","volume":"46","author":"Ostro MJ","year":"1989","journal-title":"Am J Hosp Pharm"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/8.5.371"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/145.2.748"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1164\/arrd.1982.125.5.610"},{"key":"e_1_2_1_45_2","first-page":"39","article-title":"Pharmacokinetic and therapeutic consequences of liposomal drug delivery: fluorodeoxyuridine and amphotericin B as examples","volume":"47","author":"Juliano R.","year":"1983","journal-title":"Biol Cell"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/147.5.939"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1089\/cdd.1983.1.37"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1989.00390110097022"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.85.16.6122"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.3109\/08982109309150730"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01963781"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0277-5379(98)90033-5"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/159.4.717"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.3.518"},{"key":"e_1_2_1_55_2","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1177\/106002809402801010","article-title":"Intralipid in prophylaxis of amphotericin B nephrotoxicity","volume":"28","author":"Vita E.","year":"1994","journal-title":"Ann Pharmacother"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/30.4.535"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.305.6859.921"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/31.1.161"},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199608000-00007"},{"key":"e_1_2_1_60_2","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/ajhp\/52.13.1463","article-title":"Amphotericin B does not mix with fat emulsion [letter]","volume":"52","author":"Trissel LA","year":"1995","journal-title":"Am J Health-Syst Pharm"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.1981.02130310034012"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.317.7155.379"},{"issue":"2","key":"e_1_2_1_63_2","first-page":"123","article-title":"Fate and behavior of liposomes in vivo: a review of controlling factors","volume":"3","author":"Senior JH","year":"1987","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"e_1_2_1_64_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01575123"},{"key":"e_1_2_1_65_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01575125"},{"key":"e_1_2_1_66_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/23.5.1126"},{"key":"e_1_2_1_67_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/28.suppl_B.39"},{"key":"e_1_2_1_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)90171-3"},{"key":"e_1_2_1_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5173(97)00406-7"},{"key":"e_1_2_1_70_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.7.1677"},{"key":"e_1_2_1_71_2","first-page":"105","volume-title":"Liposomes in the therapy of infectious diseases and cancer","author":"Storm G.","year":"1989"},{"key":"e_1_2_1_72_2","doi-asserted-by":"publisher","DOI":"10.1159\/000239202"},{"key":"e_1_2_1_73_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0026-895X(25)10311-8","article-title":"Mechanism of the selective toxicity of amphotericin B incorporated into liposomes","volume":"31","author":"Juliano RL","year":"1987","journal-title":"Mol Pharmacol"},{"issue":"5","key":"e_1_2_1_74_2","first-page":"S3","article-title":"AmBisome targeting to fungal infections","volume":"14","author":"Adler\u2010Moore J.","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_1_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/0168-3659(94)90207-0"},{"key":"e_1_2_1_76_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.4.767"},{"key":"e_1_2_1_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2736(92)90414-H"},{"key":"e_1_2_1_78_2","volume-title":"Cytokine expression by amphotericin B (AMB) formulations [abstr]","author":"Cleary J.","year":"1993"},{"key":"e_1_2_1_79_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1994.tb44242.x"},{"key":"e_1_2_1_80_2","unstructured":"HellmannA. RadowskaD. TrochaH. et al.A pharmaco\u2010kinetic study of Abelcet (amphotericin B lipid complex) in patients with definite or probable systemic fungal infections [abstr]. Proceedings of the 13th congress of the International Society for Human and Animal Mycology Salsomaggiore Parma Italy June 813 1997."},{"key":"e_1_2_1_81_2","volume-title":"Pharmaco\u2010kinetics of amphotericin B following administration as amphotericin B lipid complex (ABLC) or Fungizone, in adults with mucocutaneous leishmaniasis [abstr]","author":"Grasela D.","year":"1993"},{"key":"e_1_2_1_82_2","volume-title":"Abelcet (amphotericin B lipid complex injection) package insert","author":"Liposome Company","year":"1996"},{"key":"e_1_2_1_83_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.9.2042"},{"key":"e_1_2_1_84_2","volume-title":"Pharmacokinetics of AmBisome in persistently febrile neutropenic patients receiving empirical antifungal therapy [abstr]","author":"Walsh TJ","year":"1995"},{"key":"e_1_2_1_85_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/28.suppl_B.73"},{"key":"e_1_2_1_86_2","doi-asserted-by":"publisher","DOI":"10.1086\/516353"},{"key":"e_1_2_1_87_2","unstructured":"WalkerRC HiemenzJW.Amphotericin B lipid complex in systemic mycoses refractory to amphotericin B [abstr]. Proceedings of the 31st annual meeting of the American Society of Clinical Oncology Los Angeles May 23 1995."},{"key":"e_1_2_1_88_2","unstructured":"WingardJ.R. WalkerRC.Efficacy of amphotericin B lipid complex in the treatment of bone marrow transplant recipients with life\u2010threatening systemic mycoses [abstr]. In: Proceedings of the 36th annual meeting and exposition of the American Society of Hematology Nashville TN December 5 1994."},{"key":"e_1_2_1_89_2","volume-title":"Amphotericin B lipid complex in the treatment of 228 cases of invasive mycosis [abstr]","author":"Walsh TJ","year":"1994"},{"key":"e_1_2_1_90_2","unstructured":"HiemenzJW ListerJ. AnaissieEJ et al.Emergency\u2010use amphotericin B lipid complex in the treatment of patients with aspergillosis: historical\u2010control comparison with amphotericin B [abstr]. In: Proceedings of the 37th annual meeting and exposition of the American Society of Hematology Seattle WA December 5 1995."},{"key":"e_1_2_1_91_2","unstructured":"ListerJ..Amphotericin B lipid complex in the management of serious systematic mycoses in patients intolerant to amphotericin B therapy [abstr]. In: Proceedings of the 36th annual meeting and exposition of the American Society of Hematology Nashville TN December 5 1994."},{"key":"e_1_2_1_92_2","volume-title":"Amphotericin B lipid complex versus amphotericin B (AMB) for treatment of hematogenous and invasive candidiasis: a prospective, randomized, multicenter trial [abstr]","author":"Anaissie EJ","year":"1995"},{"key":"e_1_2_1_93_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/22.2.315"},{"key":"e_1_2_1_94_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/21.5.1154"},{"key":"e_1_2_1_95_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/28.suppl_B.83"},{"key":"e_1_2_1_96_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb04825.x"},{"key":"e_1_2_1_97_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.2473063.x"},{"key":"e_1_2_1_98_2","volume-title":"A randomized, double\u2010blind trial of AmBisome (liposomal amphotericin B) versus amphotericin B in the empirical treatment of persistently febrile neutropenic patients [abstr]","author":"Walsh T.","year":"1997"},{"key":"e_1_2_1_99_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199712000-00010"},{"key":"e_1_2_1_100_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199201093260202"},{"key":"e_1_2_1_101_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/173.5.1208"},{"key":"e_1_2_1_102_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/21.5.1145"},{"key":"e_1_2_1_103_2","first-page":"635","article-title":"Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis","volume":"24","author":"White MH","year":"1997","journal-title":"Clin Infect Dis"},{"key":"e_1_2_1_104_2","doi-asserted-by":"publisher","DOI":"10.1086\/516314"},{"key":"e_1_2_1_105_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01575124"},{"key":"e_1_2_1_106_2","doi-asserted-by":"publisher","DOI":"10.1097\/00019048-199803000-00004"},{"key":"e_1_2_1_107_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.4.899"},{"key":"e_1_2_1_108_2","volume-title":"Amphotericin B lipid complex (ABLC) in the treatment of coccidioidomycosis [abstr]","author":"Sharkey PK","year":"1991"},{"key":"e_1_2_1_109_2","volume-title":"Coccidioidal infections treated with amphotericin B colloidal dispersion (Amphocil or ABCD) [abstr]","author":"Hostetler JS","year":"1992"},{"key":"e_1_2_1_110_2","unstructured":"AnaissieEJ RamphalR. HorwithG..Efficacy and safety of amphotericin B lipid complex injection (Abelcet) in the treatment of patients with fusariosis [abstr]. Proceedings of the 38th annual meeting and exposition of the American Society of Hematology Orlando FL December 9 1996."},{"key":"e_1_2_1_111_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1996.00440030145018"},{"key":"e_1_2_1_112_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1995.00430140136020"},{"key":"e_1_2_1_113_2","doi-asserted-by":"publisher","DOI":"10.1086\/514562"},{"key":"e_1_2_1_114_2","doi-asserted-by":"publisher","DOI":"10.1016\/0272-6386(95)90662-2"},{"key":"e_1_2_1_115_2","first-page":"240","volume-title":"Pediatric infectious diseases: principles and practice","author":"Reed MD","year":"1995"},{"key":"e_1_2_1_116_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199207050-00003"},{"key":"e_1_2_1_117_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.9.1944"},{"key":"e_1_2_1_118_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.79.1.99"},{"key":"e_1_2_1_119_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1753-4887.1981.tb06786.x"},{"key":"e_1_2_1_120_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.66.1_Spec_No.26"},{"key":"e_1_2_1_121_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199802000-00013"},{"key":"e_1_2_1_122_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02768745"},{"key":"e_1_2_1_123_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1998.tb03118.x"},{"key":"e_1_2_1_124_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199203263261301"},{"key":"e_1_2_1_125_2","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1177\/106002809502900915","article-title":"Antifungal prophylaxis in bone marrow transplant","volume":"29","author":"Lam HH","year":"1995","journal-title":"Ann Pharmacother"},{"key":"e_1_2_1_126_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(91)90184-Y"},{"key":"e_1_2_1_127_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/165.5.891"},{"key":"e_1_2_1_128_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(94)90345-X"},{"key":"e_1_2_1_129_2","first-page":"577","article-title":"Randomized double\u2010blind study of liposomal amphotericin B (AmBisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients","volume":"12","author":"Tollemar J.","year":"1993","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_1_130_2","first-page":"1195","article-title":"Prophylaxis with liposomal amphotericin B (AmBisome) prevents fungal infections in liver transplant recipients: long\u2010term results of a randomized, placebo\u2010controlled trial","volume":"27","author":"Tollemar J.","year":"1995","journal-title":"Transplant Proc"},{"key":"e_1_2_1_131_2","volume-title":"Drug topics red book","author":"Cardinale V.","year":"1998"},{"issue":"1","key":"e_1_2_1_132_2","first-page":"501a","article-title":"Cost\u2010effectiveness analysis of AmBisome (AMB) vs. amphotericin B (AMPHOB) in the empiric treatment of febrile neutropenia in adults and children [abstr]","volume":"88","author":"Boogaerts M.","year":"1996","journal-title":"Blood"},{"key":"e_1_2_1_133_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199202060-00008"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.19.4.306.30934","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.19.4.306.30934","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:12:46Z","timestamp":1761052366000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.19.4.306.30934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,3]]},"references-count":132,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1999,3]]}},"alternative-id":["10.1592\/phco.19.4.306.30934"],"URL":"https:\/\/doi.org\/10.1592\/phco.19.4.306.30934","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,3]]},"assertion":[{"value":"2012-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}